MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting | Zendy

Luis OstroskyZeichner | Zendy; Shmuel Shoham | Zendy; José A. Vázquez | Zendy; Annette C. Reboli | Zendy; Robert F. Betts | Zendy; Michelle Barron | Zendy; Mindy G. Schuster | Zendy; Marc A. Judson | Zendy; Sanjay G. Revankar | Zendy; Juan Pablo Caeiro | Zendy; Julie E. Mangino | Zendy; David Mushatt | Zendy; Roger Bedimo | Zendy; Alison G. Freifeld | Zendy; M. Hong Nguyen | Zendy; Carol A. Kauffman | Zendy; William E. Dismukes | Zendy; Andrew O. Westfall | Zendy; J. B. Deerman | Zendy; G. Christopher Wood | Zendy; Jack D. Sobel | Zendy; Peter G. Pappas | Zendy

Open Access

MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting

Author(s) -

Luis OstroskyZeichner,

Shmuel Shoham,

José A. Vázquez,

Annette C. Reboli,

Robert F. Betts,

Michelle Barron,

Mindy G. Schuster,

Marc A. Judson,

Sanjay G. Revankar,

Juan Pablo Caeiro,

Julie E. Mangino,

David Mushatt,

Roger Bedimo,

Alison G. Freifeld,

M. Hong Nguyen,

Carol A. Kauffman,

William E. Dismukes,

Andrew O. Westfall,

J. B. Deerman,

G. Christopher Wood,

Jack D. Sobel,

Peter G. Pappas

Publication year - 2014

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciu074

Subject(s) - medicine , caspofungin , invasive candidiasis , placebo , randomized controlled trial , intensive care medicine , antifungal , fluconazole , dermatology , alternative medicine , pathology

Invasive candidiasis is the third most common bloodstream infection in the intensive care unit (ICU) and is associated with morbidity and mortality. Prophylaxis and preemptive therapy are attractive strategies for this setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research